<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3648">
  <stage>Registered</stage>
  <submitdate>13/09/2012</submitdate>
  <approvaldate>13/09/2012</approvaldate>
  <nctid>NCT01691859</nctid>
  <trial_identification>
    <studytitle>MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects</studytitle>
    <scientifictitle>MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>115666</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Mepolizumab

Experimental: Mepolizumab - Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.


Treatment: drugs: Mepolizumab
100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequency of all Adverse Events - Frequency of all Adverse Events</outcome>
      <timepoint>48 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>ECG parameters - ECG parameters as measured by mean change and maximum change from baseline in QTcF and QT</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical laboratory tests - Clinical laboratory tests as measured by abnormal parameters for hematology and clinical chemistry</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital Signs - Vital signs as measured by change in pulse and BP from baseline</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Annualized rate of exacerbation - Annualized rate of exacerbation</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life (QOL) - QOL as measured by Asthma Control Questionnaire score (ACQ)-5</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung Function - Lung function as measured by changes from baseline in Forced vital capacity (FVC) and Forced expiratory volume in 1 second (FEV1) measured by clinic spirometry</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenecity - Immunogenecity as measured by positive neutralizing antibody</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participant withdrawals - Number of participant withdrawals due to lack of efficacy or due to adverse events were summarized</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of hospitalizations due to adverse events including asthma exacerbations - Number of hospitalizations due to adverse events including asthma exacerbations</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of immune reactions - Frequency of immune reactions</outcome>
      <timepoint>48 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed Consent.

          -  MEA112997 Study Participation: Received at least 2 doses of double-blind
             investigational product during the MEA112997 trial.

          -  MEA112997 Treatment Assignment: If the subject received mepolizumab, they must have
             had a positive risk: benefit ratio.

          -  Currently being treated with a controller medication and the subject has been on a
             controller medication for the past 12 weeks.

          -  Male or Eligible Female Subjects. To be eligible for entry into the study, females of
             childbearing potential must commit to consistent and correct use of an acceptable
             method of birth control for the duration of the trial and for 4 months after the last
             study drug administration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Hypersensitivity related to mepolizumab.

          -  Clinically significant change in health status since completing participation in the
             MEA112997 trial.

          -  A current malignancy or previous history of cancer in remission for less than 12
             months prior to screening.

          -  For those subjects who had a SAE in MEA112997 that was assessed as possibly related to
             mepolizumab by the investigator.

          -  Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they
             plan to become pregnant during the time of study participation.

          -  Screening ECG which has a clinically significant abnormality.

          -  Received Xolair (omalizumab) within the past 130 days.

          -  Participated in a clinical trial within the past 30 days or have received
             investigational medication within five terminal half-lives of Screen Visit, whichever
             is longer.

          -  Current smokers.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>28/09/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>347</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/05/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>GSK Investigational Site - New Lambton</hospital>
    <hospital>GSK Investigational Site - Adelaide</hospital>
    <hospital>GSK Investigational Site - Clayton</hospital>
    <hospital>GSK Investigational Site - Melbourne</hospital>
    <hospital>GSK Investigational Site - Nedlands</hospital>
    <postcode>2305 - New Lambton</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autónoma de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Mendoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Región Metro De Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Valparaíso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Talcahuano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremlin-Bicêtre Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille cedex 20</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Pierre cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Brandenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinland-Pfalz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schleswig-Holstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Cheongju, Chungcheongbuk-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon, Kyonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targu Mures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Barnaul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Chelyabinsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St'Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Donetsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicestershire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab
      administered subcutaneously (SC) in addition to standard of care in subjects who participated
      in the MEA112997 study. At each clinic visit, adverse events will be assessed and
      exacerbations will also be reviewed.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01691859</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>